18 recruiting, 9 completed, 8 unknown, 3 not yet recruiting. 21 Phase 2, 14 Phase 3, 3 Not applicable, 2 Phase 1.
Follow Concurrent Chemotherapy: new trials by email Literature Review of Concurrent Chemotherapy trials Research Report on Concurrent Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC Induction chemoimmunotherapy, radiotherapy, Concurrent Chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 256 | 2026-10-12 | 2026-10-14 |
| The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer Definitive radiotherapy, BCG, Concurrent chemotherapy - Non Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Assiut University | 70 | 2026-10-02 | 2026-10-14 |
| Hypofractionated Chemoradiotherapy for Cervical Cancer Hypofractionated Chemoradiotherapy, Conventional Chemoradiotherapy, Concurrent chemotherapy - Cervival Cancer | Phase 3 | Recruiting | Mahidol University | 250 | 2026-08-03 | 2026-08-24 |
| Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC Radiotherapy, Concurrent chemotherapy, Tislelizumab - NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Sun Yat-sen University | 160 | 2026-06-01 | 2026-07-01 |
| A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT standard EBRT+Brachytherapy, Concurrent chemotherapy, Immune induction therapy - Locally Advanced Cervical Carcinoma | Phase 3 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 378 | 2026-04-24 | 2026-05-13 |
| Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer Definitive hypofractionated intensity-modulated radiation theraphy, concurrent chemotherapy - Cervical Cancer | Phase 2 | Recruiting | Samsung Medical Center | 34 | 2025-12-09 | 2026-02-27 |
| Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 456 | 2025-11-18 | 2026-01-09 |
| Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost), GTV 50 Gy/25 fractions(Simultaneous Integrated Boost), Concurrent Chemotherapy - Locally Advanced Rectal Adenocarcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 156 | 2025-10-01 | 2026-09-21 |
| Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer Surufatinib, Tislelizumab, Concurrent Chemotherapy - Surufatinib, Tislelizumab | Phase 2 | Recruiting | Sun Yat-sen University | 80 | 2025-07-20 | 2025-07-25 |
| Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 69 | 2025-07-20 | 2025-11-17 |
| Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC Hypofractionated Radiation Therapy, Conventionally Fractionated Radiation Therapy, Concurrent Chemotherapy - Locally Advanced Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Sun Yat-sen University | 311 | 2025-07-01 | 2025-07-23 |
| Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 134 | 2025-04-05 | 2025-11-17 |
| Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC Intensity-modulated proton radiation therapy, Intensity-modulated photon radiation therapy, Intensity-modulated carbon ion radiation therapy - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Lin Kong, MD | 470 | 2025-04-01 | 2025-12-02 |
| Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma Radiotherapy, Concurrent chemotherapy, Methylprednisolone - Thymoma | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2024-11-20 | 2024-12-12 |
| Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT, Concurrent chemotherapy - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Sun Yat-sen University | 490 | 2024-08-01 | 2026-04-06 |
| Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. Full course of PD-1/PD-L1 blockades, Cisplatin-based induction chemotherapy, Standard-dose IMRT - Nasopharyngeal Carcinoma, De-escalation Therapy | Phase 3 | Recruiting | Sun Yat-sen University | 586 | 2024-07-30 | 2024-11-05 |
| IC Plus Low-dose Radiation Plus Cadonilimab in LANPC Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor | Phase 3 | Recruiting | Sun Yat-sen University | 380 | 2024-01-10 | 2026-05-11 |
| Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT - Nasopharyngeal Carcinoma, De-escalation Therapy | Phase 3 | Recruiting | Sun Yat-sen University | 504 | 2023-10-09 | 2023-12-15 |
| Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy - Esophageal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | Sun Yat-sen University | 18 | 2023-08-31 | 2025-07-21 |
| The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 114 | 2023-07-25 | 2026-08-03 |
Showing 20 of 40. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Nasopharyngeal Carcinoma (7) · Uterine Cervical Neoplasms (4) · Esophageal Squamous Cell Carcinoma (3) · Adenocarcinoma of Lung (2) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Mucositis (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Pancreatic Neoplasms (1) · Pathologic Complete Response (1) · Rectal Neoplasms (1)
Sun Yat-sen University (25) · Peking Union Medical College Hospital (2) · Assiut University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · First Affiliated Hospital of Harbin Medical University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Lin Kong, MD (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mahidol University (1) · Ming-Yuan Chen (1) · Samsung Medical Center (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Trans Tasman Radiation Oncology Group (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Zhejiang Cancer Hospital (1)
China (35) · Australia (1) · Canada (1) · New Zealand (1) · South Korea (1) · Thailand (1)
Hui Liu, Professor (8) · Hui Liu (3) · Ming-Yuan Chen, MD,PhD (3) · Hui Liu, Ph.D (2) · Chengfeng Wang, B.A. (1) · Chong Zhao, MD, PhD (1) · Fang-Yun Xie, M.D (1) · Guiling Li, PHD (1) · Hui Liu, Doctor (1) · Hui Liu, Prof. (1) · Hui Liu, professor (1) · Ke Hu (1) · Lucas C Mendez, MD (1) · Sam Ngan, FRANZCR (1) · Xiang-bo Wan, PhD (1)
PMID 35905860, PMID 20354531, PMID 20956625, PMID 23008301, PMID 23578724, PMID 24035327, PMID 27631775, PMID 28453692, PMID 31534737, PMID 33933895, PMID 37100160, PMID 42028290, PMID 42436536, PMID 4830803, PMID 8874455